KODIAK SCIENCES INC. (KOD)
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak business signals • Minimal market impact **Sentiment:** Neutral (50%) **Content type:** Business